Biodegradable Polymeric Nanoparticles for Drug Delivery to Solid Tumors (original) (raw)
Related papers
Polymeric Nanoparticles—Tools in a Drug Delivery System in Selected Cancer Therapies
Applied Sciences
The increase in cancer cases is undoubtedly affecting the development of new therapeutic approaches. Polymeric nanoparticles are of great interest. Due to their relatively small size, the possibility of incorporating into them medicinal substances and the ease with which their physicochemical properties may be manipulated, they are being used as anticancer drug delivery systems. The aim of this review is to focus on the use of nanoscale polymeric particles in the treatment of colorectal cancer, breast cancer, ovarian cancer and glioblastoma multiforme, and to consider their potential use in cancer gene therapy. According to several reports, the use of polymer nanoparticles as drug carriers is promising in solid tumors. With their application, it is possible to precisely deliver medicinal substances to the tumor structure, to overcome the blood–brain barrier in the case of brain tumors, to reduce the side effects of anticancer agents on normal cells and to achieve a therapeutic effec...
Anti-cancer nanoparticulate drug delivery system using biodegradable polymers
2013
A B ST R A C T Cancer is a hyper proliferative disorder marked by metastasis into the vital organs of the body through invasion and angiogenesis. Biodegradable nanoparticles have been used frequently as anti-cancer drug delivery vehicles due to its splendid bioavailability, better encapsulation, and control release with less toxic properties. Various nanoparticulate systems, general synthesis and encapsulation process, control release and improvement of therapeutic value of nano-encapsulated cancer drugs are covered in this review. We have highlighted the impact of biodegradable polymer such as PLGA, PLA, chitosan, gelatin, polycaprolactone and poly-alkyl-cyanoacrylates in the formulation of nanoparticles for encapsulation of cancer drugs. Hence in the current review a detailed studied has been done for the delivering of cancer drugs effectively using biodegradable polymers.
Multifunctional Polymeric Nanosystems for Tumor-Targeted Delivery
Cancer is the second leading cause of morbidity and mortality in the United States, with occurrences portraying an upward trend for the future. In 2007, approximately 10 million cases of cancer will occur globally, with a total of around 1.5 million new cancer cases and over 560,000 deaths expected in the United States (U.S. National Institute of Health, 2006). Strikingly, remarkable advances in diagnosis and therapy of cancer have been made over the past few decades resulting from significant advances in fundamental cancer biology. What lacks in this case is clinical translation of these advances into effective therapies. A major hurdle in cancer diagnosis and therapy is the targeted and efficacious delivery of agents to the tumor site, while avoiding adverse damage resulting from systemic administration. While systemic drug delivery already hinges largely on physicochemical properties of the drug, such as size, diffusivity, and plasma protein binding affinity, tumors possess a dense, heterogeneous vasculature and an outward net convective flow that act as hurdles to efficient drug deposition at the target site (Jang et al., 2003). Nanocarriermediated delivery has emerged as a successful strategy to enhance delivery of therapeutics and imaging agents to tumors, thereby increasing the potential for diagnosis at an earlier stage or for therapeutic success (or both). Based on the initial observation by Maeda and Matsumura that tumors possess a fenestrated vasculature, with pores on average ranging between 200 and 800 nm, and a lack of lymphatic drainage, together termed the enhanced permeability and retention (EPR) effect, it was found that colloidal carriers in the nanometer size range could target tumors passively, by specific extravasation through these fenestrations, and are retained at the site for prolonged time because of lack of lymphatic drainage (Matsumura and Meada, 1986). This physiological advantage has been used successfully to enhance delivery of diagnostic and therapeutic agents, leading to the U.S. Food and Drug Administration (FDA) approval of nanoparticle formulations such as Feridex® for diagnostic applications and Doxil® and Abraxane® for cancer therapy (U.S. Food and Drug Administration, 2006).
Functionalized Polymeric Nanoparticles: A Novel Targeted Approach for Oncology Care
International Journal of Applied Pharmaceutics
Popular cancer therapies face extreme disadvantages, including multimedicament tolerance and non-target impact. These issues will lead to poorer patient conformity and poor levels of survival. Successful medical therapies for cancer patients are desperately required. Nano-particulate structures with a pluronic base represent revolutionary platforms for anti-cancer agent provision. These structures provide great potential for the advancement of cancer therapy due to their pharmacological properties and sufficient physicochemical characteristics. This review aims to offer a more detailed description of the pluronic drug delivery mechani sms that are currently available and explains pluronic as a medicinal polymer. Hydrophobic payload formulations and updated, targeted distribution mechanisms are explained based on pluronic formulations. This analysis offers a rundown of the current situation art related to the theranostic application of polymer micelles targeting the microenvironment ...
African Journal of Pharmacy and Pharmacology, 2013
The main aim of the present work was to formulate anti-neoplastic drug loaded polymeric nanoparticles using biodegradable polymers (Chitosan and Eudragit RS 100) by emulsion droplet coalescence method. The model drug used here is 5-fluorouracil which is a pyrimidine analogue that is mainly used to treat colonic carcinoma, under the category of anti-neoplastic drugs. Tween 20 was used as emulsifier and colloidal stabilizer. The prepared nanoparticles were evaluated for particle size, surface morphology by TEM, surface charge, drug loading and entrapment efficiency, and for drug release by diffusion. Results show that the prepared nanoparticles are in nanosize, below 1000 nm, having appropriate zeta potential values with better entrapment of drug and controlled release of drug for a period of 12 h. From the obtained formulations, EF5 was selected as best with high entrapment efficiency, optimum zeta potential, and showing more controlled release of drug.
Polymeric Nanoparticles for Drug Delivery
Methods in Molecular Biology, 2010
The use of biodegradable polymeric nanoparticles (NPs) for controlled drug delivery has shown significant therapeutic potential. Concurrently, targeted delivery technologies are becoming increasingly important as a scientific area of investigation. In cancer, targeted polymeric NPs can be used to deliver chemotherapies to tumor cells with greater efficacy and reduced cytotoxicity on peripheral healthy tissues. In this chapter, we describe the methods of (1) preparation and characterization of drug-encapsulated polymeric NPs formulated with biocompatible and biodegradable poly(D,L-lactic-co-glycolic acid)poly(ethylene glycol) (PLGA-b-PEG) copolymers; (2) surface functionalization of the polymeric NPs with the A10 2-fluoropyrimidine ribonucleic acid (RNA) aptamers that recognize the prostate-specific membrane antigen (PSMA) on prostate cancer cells; and (3) evaluation of the binding properties of these targeted polymeric NPs to PSMA-expressing prostate cancer cells in vitro and in vivo. These methods may contribute to the development of other useful polymeric NPs to deliver a spectrum of chemotherapeutic, diagnostic, and imaging agents for various applications.
Perspective highlights on biodegradable polymeric nanosystems for targeted therapy of solid tumors
BioImpacts
Introduction: Polymeric nanoparticles (NPs) formulated using biodegradable polymers offer great potential for development of de novo drug delivery systems (DDSs) capable of delivering a wide range of bioactive agents. They can be engineered as advanced multifunctional nanosystems (NSs) for simultaneous imaging and therapy known as theranostics or diapeutics. Methods: A brief prospective is provided on biomedical importance and applications of biodegradable polymeric NSs through reviewing the recently published literature. Results: Biodegradable polymeric NPs present unique characteristics, including: nanoscaled structures, high encapsulation capacity, biocompatibility with non-thrombogenic and nonimmunogenic properties, and controlled-/sustained-release profile for lipophilic and hydrophilic drugs. Once administered in vivo, all classes of biodegradable polymers (i.e., synthetic, semi-synthetic, and natural polymers) are subjected to enzymatic degradation; and hence, transformation into byproducts that can be simply eliminated from the human body. Natural and semi-synthetic polymers have been shown to be highly stable, much safer, and offer a non-/lesstoxic means for specific delivery of cargo drugs in comparison with synthetic polymers. Despite being biocompatible and enzymatically-degradable, there are some drawbacks associated with these polymers such as batch to batch variation, high production cost, structural complexity, lower bioadhesive potential, uncontrolled rate of hydration, and possibility of microbial spoilage. These pitfalls have bolded the importance of synthetic counterparts despite their somewhat toxicity. Conclusion: Taken all, to minimize the inadvertent effects of these polymers and to engineer much safer NSs, it is necessary to devise biopolymers with desirable chemical and biochemical modification(s) and polyelectrolyte complex formation to improve their drug delivery capacity in vivo.
Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research
Clinical and Translational Oncology, 2012
Conventional anticancer drugs display signifi cant shortcomings which limit their use in cancer therapy. For this reason, important progress has been achieved in the fi eld of nanotechnology to solve these problems and offer a promising and effective alternative for cancer treatment. Nanoparticle drug delivery systems exploit the abnormal characteristics of tumour tissues to selectively target their payloads to cancer cells, either by passive, active or triggered targeting. Additionally, nanoparticles can be easily tuned to improve their properties, thereby increasing the therapeutic index of the drug. Liposomes, polymeric nanoparticles, polymeric micelles and polymer-or lipid-drug conjugate nanoparticles incorporating cytotoxic therapeutics have been developed; some of them are already on the market and others are under clinical and preclinical research. However, there is still much research to be done to be able to defeat the limitations of traditional anticancer therapy. This review focuses on the potential of nanoparticle delivery systems in cancer treatment and the current advances achieved.